| 货号 | 包装规格 | 操作 |
|---|---|---|
| SML4035-5MG | 5 mg | |
| SML4035-25MG | 25 mg |
≥97%
Potent glycine site-selective NMDA receptor antagonist with anticonvulsant efficacy in vivo.
CGP 78608 (PAMQX) is a potent glycine site-selective NMDA receptor antagonist (IC50 = 5 nM by competitive binding against 5 nM [3H]MDL 105,519; IC50 = 3/2.7 μM against AMPA/kainate, >10 μM against CGP39653 (glutamate site) and channel blocker MK-801) that exhibits anticonvulsant efficacy in mice in vivo (electroshock-induced convulsion ED50 = 12 mg/kg i.p.).
| 英文名称 | CGP 78608 hydrochloride |
| CAS 号 | 1135278-54-4 |
| 经验分子式 | C11H13BrN3O5P·HCl |
| 分子量 | 414.58 |
| MDL 号 | MFCD06798371 |
| NACRES | NA.21 |
| SMILES字符串 | BrC1=CC(NC2=O)=C(C(CN[C@@H](P(O)(O)=O)C)=C1)NC2=O.Cl |
| 含量测定 | ≥97% |
| 形态 | 粉末 |
| 储存条件 | 干燥 |
| 颜色 | 白色至米色 |
| 溶解性 | 二甲基亚砜（DMSO）：2 毫克/毫升，透明（加热） |
| 储存温度 | -10 到 -25°C |
| 质量等级 | 100 |
| 包装规格（货号 SML4035-5MG） | 5 mg |
| 包装规格（货号 SML4035-25MG） | 25 mg |
